These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 31107542)

  • 1. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
    Boige V; Mollevi C; Gourgou S; Azria D; Seitz JF; Vincent M; Bigot L; Juzyna B; Miran I; Gerard JP; Laurent-Puig P
    Int J Cancer; 2019 Dec; 145(11):3163-3172. PubMed ID: 31107542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer.
    Chen W; Wang W; Li Y; Dong H; Wang G; Li X
    Cancer Cell Int; 2018; 18():123. PubMed ID: 30181716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.
    Nikas JB; Lee JT; Maring ED; Washechek-Aletto J; Felmlee-Devine D; Johnson RA; Smyrk TC; Tawadros PS; Boardman LA; Steer CJ
    Am J Cancer Res; 2015; 5(10):3231-40. PubMed ID: 26693073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
    van der Valk MJM; Marijnen CAM; van Etten B; Dijkstra EA; Hilling DE; Kranenbarg EM; Putter H; Roodvoets AGH; Bahadoer RR; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes AMR; de Groot DJA; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Radiother Oncol; 2020 Jun; 147():75-83. PubMed ID: 32240909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
    Charton E; Bachet JB; Hammel P; Desramé J; Chibaudel B; Cohen R; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Guerin-Meyer V; Taieb J; Volet J; Louvet C; Anota A; Bonnetain F
    Cancer Med; 2019 Sep; 8(11):5079-5088. PubMed ID: 31314957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.
    Petrelli F; Trevisan F; Cabiddu M; Sgroi G; Bruschieri L; Rausa E; Ghidini M; Turati L
    Ann Surg; 2020 Mar; 271(3):440-448. PubMed ID: 31318794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
    Boilève A; Hilmi M; Gougis P; Cohen R; Rousseau B; Blanc JF; Ben Abdelghani M; Castanié H; Dahan L; Tougeron D; Metges JP; Tournigand C; Garcia-Larnicol ML; Vernerey D; Turpin A; Neuzillet C
    Eur J Cancer; 2021 Jan; 143():55-63. PubMed ID: 33279854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
    Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).
    Samalin E; Fouchardière C; Thézenas S; Boige V; Senellart H; Guimbaud R; Taïeb J; François E; Galais MP; Lièvre A; Seitz JF; Metges JP; Bouché O; Boissière-Michot F; Lopez-Crapez E; Bibeau F; Ho-Pun-Cheung A; Ychou M; Adenis A; Di Fiore F; Mazard T
    Clin Colorectal Cancer; 2020 Dec; 19(4):301-310.e1. PubMed ID: 32737004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
    Zeidan AM; Boddu PC; Patnaik MM; Bewersdorf JP; Stahl M; Rampal RK; Shallis R; Steensma DP; Savona MR; Sekeres MA; Roboz GJ; DeAngelo DJ; Schuh AC; Padron E; Zeidner JF; Walter RB; Onida F; Fathi A; DeZern A; Hobbs G; Stein EM; Vyas P; Wei AH; Bowen DT; Montesinos P; Griffiths EA; Verma AK; Keyzner A; Bar-Natan M; Navada SC; Kremyanskaya M; Goldberg AD; Al-Kali A; Heaney ML; Nazha A; Salman H; Luger S; Pratz KW; Konig H; Komrokji R; Deininger M; Cirici BX; Bhatt VR; Silverman LR; Erba HP; Fenaux P; Platzbecker U; Santini V; Wang ES; Tallman MS; Stone RM; Mascarenhas J
    Lancet Haematol; 2020 Aug; 7(8):e601-e612. PubMed ID: 32563283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
    Cohen R; Vernerey D; Bellera C; Meurisse A; Henriques J; Paoletti X; Rousseau B; Alberts S; Aparicio T; Boukovinas I; Gill S; Goldberg RM; Grothey A; Hamaguchi T; Iveson T; Kerr R; Labianca R; Lonardi S; Meyerhardt J; Paul J; Punt CJA; Saltz L; Saunders MP; Schmoll HJ; Shah M; Sobrero A; Souglakos I; Taieb J; Takashima A; Wagner AD; Ychou M; Bonnetain F; Gourgou S; Yoshino T; Yothers G; de Gramont A; Shi Q; André T;
    Eur J Cancer; 2020 May; 130():63-71. PubMed ID: 32172199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
    Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
    Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
    Hammel P; Fabienne P; Mineur L; Metges JP; Andre T; De La Fouchardiere C; Louvet C; El Hajbi F; Faroux R; Guimbaud R; Tougeron D; Bouche O; Lecomte T; Rebischung C; Tournigand C; Cros J; Kay R; Hamm A; Gupta A; Bachet JB; El Hariry I
    Eur J Cancer; 2020 Jan; 124():91-101. PubMed ID: 31760314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
    Walter T; Lepage C; Coriat R; Barbier E; Cadiot G; Caroli-Bosc FX; Aparicio T; Bouhier-Leporrier K; Hentic-Dhome O; Gay F; Dupont-Gossart AC; Duluc M; Lepere C; Lecomte T; Smith D; Petorin C; Di-Fiore F; Ghiringhelli F; Legoux JL; Guimbaud R; Baudin E; Lombard-Bohas C; de Baère T;
    Eur J Cancer; 2019 Dec; 123():92-100. PubMed ID: 31678771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
    Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
    Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
    Tallman MS; Wang ES; Altman JK; Appelbaum FR; Bhatt VR; Bixby D; Coutre SE; De Lima M; Fathi AT; Fiorella M; Foran JM; Hall AC; Jacoby M; Lancet J; LeBlanc TW; Mannis G; Marcucci G; Martin MG; Mims A; O'Donnell MR; Olin R; Peker D; Perl A; Pollyea DA; Pratz K; Prebet T; Ravandi F; Shami PJ; Stone RM; Strickland SA; Wieduwilt M; Gregory KM; ; Hammond L; Ogba N
    J Natl Compr Canc Netw; 2019 Jun; 17(6):721-749. PubMed ID: 31200351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
    Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
    Papaccio F; Roselló S; Huerta M; Gambardella V; Tarazona N; Fleitas T; Roda D; Cervantes A
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.
    Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.